BioSpace News Archive

Drug Development

NANOBIOTIX Reports Updated Phase 1 Anti-PD-1 Combination Data That May Support the Immune Stimulation Potential of Radioenhancer NBTXR3 at the 37th Annual Meeting of the Society for Immunotherapy of Cancer

NANOBIOTIX, a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, announced updated data from the Company’s phase 1 immunotherapy study, Study 1100.

November 10, 2022
·
11 min read
Business

Novozymes and LinusBio announce collaboration to accelerate scientific discovery in Biohealth

Novozymes, the world leader in biological solutions, and LinusBio, a leader in precision exposome sequencing, announced the companies are forming a collaboration to test a new, non-invasive technology in a clinical trial.

November 10, 2022
·
4 min read
Business

Immunovia Publishes Interim Report Jan-Sep 2022

Q3 has been a quarter focussed on commercial execution and taking further steps towards reimbursement to make our innovative IMMRay PanCan-d test, the first dedicated test for early detection of pancreatic cancer, broadly available in the US.

November 10, 2022
·
6 min read
Evaxion CEO comments on strategic focus

Evaxion Biotech A/S announced that it intends to further increase its focus on its lead oncology assets EVX-01 and EVX-02/03 to bring them to clinical proof of concept followed by out-licensing.

November 10, 2022
·
5 min read
Alvotech to Present Switching Study Data for AVT02, a Proposed Biosimilar to Humira®, at 2022 American College of Rheumatology Conference

Alvotech announced that it will present two posters and will be featured in an Ignite Talk related to its switching study for ATV02 at the American College of Rheumatology Convergence Conference, being held in Philadelphia on November 10-14, 2022.

November 10, 2022
·
9 min read
Biotech Beach

MannKind to Present Two Posters at 22nd Annual Diabetes Technology Meeting

MannKind Corporation announced that it will present data from two posters on November 10 during the 22nd Annual Diabetes Technology Meeting’s virtual poster session.

November 10, 2022
·
4 min read
Business

Celyad Oncology Announces Third Quarter 2022 Financial Results and Recent Business Highlights

Celyad Oncology SA provided an update on its financial results and recent business developments for the fiscal quarter ended September 30, 2022.

November 10, 2022
·
7 min read
Pharm Country

Cellectis Publishes Manuscript in Frontiers Bioengineering and Biotechnology Unveiling Efficient Multitool/Multiplex Gene Engineering combining TALEN® and TALE Base Editors (TALE-BE)

Cellectis published a manuscript in Frontiers Bioengineering and Biotechnology demonstrating the feasibility of efficient multiplex gene engineering using a combination of two different molecular tools: Cellectis’ TALEN® gene editing technology and a TALE-BE.

November 10, 2022
·
5 min read
Sirona Biochem Signs Research Collaboration Agreement with International Centre for Genetic Engineering and Biotechnology

Sirona Biochem Corp. is pleased to announce it has entered into a research collaboration with the International Centre for Genetic Engineering and Biotechnology to advance Sirona’s antiviral library of compounds.

November 10, 2022
·
4 min read
Business

Sol-Gel Technologies Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Sol-Gel Technologies, Ltd., a dermatology company focused on identifying, developing, commercializing or partnering branded and generic topical drug products for the treatment of skin diseases, announced financial results for the third quarter ended September 30, 2022 and provided a corporate update.

November 10, 2022
·
10 min read